drugset / Trial / NCT00291837
CT-2106 for the Second Line Treatment of Ovarian Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this sudy is to determine the response rate of CT-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.
Timeline
- Start
- 2004-11
- Primary completion
- 2006-06
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT-2106 | Other / unclassified | — | — |